Quarterly ResultApr 30, 2026, 07:07 AM
ACIU Q1 Update: $12M Takeda Milestone; Lilly Tau Deal CHF10M Upfront
AI Summary
AC Immune SA reported a net loss of CHF 14.8 million for Q1 2026, an improvement from CHF 19.0 million in Q1 2025, with cash resources of CHF 74.8 million expected to fund operations into Q4 2027. The company initiated the final AD4 cohort in the ACI-24 ABATE trial, triggering a $12 million milestone payment from Takeda. Additionally, an amended Morphomer® Tau collaboration with Eli Lilly includes a CHF 10 million upfront payment and potential future milestones exceeding CHF 1.7 billion. AC Immune also dosed the first subjects in its Phase 1 trial for NLRP3 inhibitor ACI-19764 and presented promising interim data for ACI-7104 in Parkinson's disease.
Key Highlights
- Initiated final AD4 cohort for ACI-24, triggering $12M milestone payment from Takeda.
- Amended Morphomer® Tau deal with Lilly includes CHF 10M upfront payment.
- Eligible for over CHF 1.7B in future milestones plus tiered royalties from Lilly Tau deal.
- Dosed first subjects in Phase 1 trial of brain-penetrant NLRP3 inhibitor ACI-19764.
- Q1 2026 net loss of CHF 14.8M, improved from CHF 19.0M in Q1 2025.
- Cash resources of CHF 74.8M as of March 31, 2026, provide funding into Q4 2027.
- R&D expenses decreased to CHF 11.8M in Q1 2026 from CHF 15.9M in Q1 2025.